Effect of Rosuvastatin in Expression of Tim-3
Phase 4
Recruiting
- Conditions
- Chronic Hepatitis B.Chronic viral hepatitis B without delta-agentB18.1
- Registration Number
- IRCT20190602043789N1
- Lead Sponsor
- Gorgan University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Patients with Chronic Hepatitis B
Age range 20-50 years
Exclusion Criteria
Patient's unwillingness to continue participating in the study
Acute kidney failure and dialysis
Immune system disorders
Malignancies
Use of Immunosuppressive drugs
Surgery over the past 3 months
Statin Allergy
Alcohol and drug addiction...
Pregnancy
Inability to visit the clinic
Cirrhosis
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The percentage of NK cells containing Tim3 Protein. Timepoint: Three Months after taking Rosuvastatin Tablets. Method of measurement: By kit in blood samples.;The percentage of NKT cells containing Tim3 Protein. Timepoint: Three Months after taking Rosuvastatin Tablets. Method of measurement: By kit in blood samples.
- Secondary Outcome Measures
Name Time Method